Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Advanced Cancer 6Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Malignancies Multiple 1Lung Neoplasms 1Head and Neck Neoplasms 1Advanced Gastric Cancer 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × linrodostat × Clear all
NCT03312426 2018-01-19

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

Bristol-Myers Squibb

Phase 1 Completed
32 enrolled
Tumor-Agnostic

Neoplasms

NCT03247283 2017-11-06

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Bristol-Myers Squibb

Phase 1 Completed
9 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡